Compare Heron Therapeutics Inc (HRTX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Novo Nordisk A/S — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Novo Nordisk A/S trades at $49.32 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 2411.2× Heron Therapeutics Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | NVO | |
|---|---|---|
Market Cap | $91.46M | $220.53B |
Sector | Health | Health |
52-Week High | $1.96 | $71.70 |
52-Week Low | $0.39 | $35.29 |
Enterprise Value | $189.36M | $239.49B |
Dividend Yield | — | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
